Skip to content
+31618493956 info@djpc.eu

De Jong Pharma Consult

Your Quality Assurance Specialist

  • Home
    • Responsible Person
    • Supplier Audits
    • Quality Assurance Consultancy
    • Internal Audits
    • Expert GMP Oversight for Radiopharmaceuticals
      • PET Tracer Manufacturing Under GMP: Expertise You Can Rely On
      • GMP Expertise in Radiolabeled Pharmaceuticals for Human Mass Balance Trials
    • GMP Audit Training Courses for the Pharmaceutical Industry
      • Supplier Auditor Training for the Pharmaceutical Industry
      • Internal Auditor Training for the Pharmaceutical Industry
  • Blog
  • Contact
    • We work for:
    • Privacy Policy
Close Button

PET Tracer Manufacturing Under GMP: Expertise You Can Rely On

Positron Emission Tomography (PET) is a cornerstone of modern diagnostic imaging, allowing for non-invasive, real-time visualization of physiological processes. The tracers used in PET — typically radiolabeled small molecules — must be manufactured and controlled with speed, sterility, and full regulatory compliance. Their short half-life, limited stability, and need for immediate use make PET tracers among the most technically demanding radiopharmaceuticals to produce.

With a strong background in GMP auditing, compliance consulting, and radiopharmaceutical QA, I bring deep expertise in the manufacture, quality control, and release of PET tracers used across clinical research and diagnostic imaging — including products like Amyvid®, custom amyloid ligands, and fluorine-18 or carbon-11–based tracers.

Complex Products, Streamlined Oversight

The production of PET tracers typically follows a 3-step process:

  1. Cyclotron-based isotope production (e.g., [¹⁸F], [¹¹C], [¹⁵O]) – non-GMP raw material step
  2. Automated synthesis and sterile filtration – this is the GMP-critical step
  3. Dispensing into patient-specific vials and on-site injection – final preparation and use

The core of my expertise lies in auditing and validating GMP step 2 operations:

  • Automated synthesis in hot cells
  • Use of validated kits, traceability, and aseptic dispensing
  • Sterility assurance under time constraints, including provisional QP release procedures before full sterility data are available

This release-before-sterility model, while unusual, is fully accepted by regulators under 21 CFR Part 212 (US) and Eudralex Volume 4, Annex 3 (EU). I have successfully audited PET facilities across North America and Europe, ensuring these practices meet the expectations of local competent authorities, sponsor QA teams, and compound-owners such as Avid/Eli Lilly.


Key Takeaways

✅ GMP manufacturing of PET tracers must balance sterility, speed, and regulatory acceptance—requiring validated processes, qualified equipment, and auditable traceability.

✅ Auditor expertise in PET production ensures that high-risk steps like sterile filtration, endotoxin control, and documentation for investigational use are fully compliant with FDA, EMA, and national agencies like FANC.


Want Your PET Manufacturing Audit-Ready?

If your facility produces or licenses out PET tracers, you need an expert who understands GMP intricacies specific to short-lived radiopharmaceuticals. I offer audits, gap assessments, and quality system reviews that are practical, timely, and inspection-ready.

📩 Contact me today for expert support in PET tracer compliance and GMP manufacturing.

Archive

  • June 2025
  • May 2025

Categories

  • Responsible Person
  • Supplier Audits
  • When Audits Turn Hostile: A Lesson in GMP Compliance
  • Enforcing GDP Compliance: A Responsible Person’s Unforgettable Lesson
  • The Cat in the Warehouse: When Pest Control Goes Feline

Social Media

  • Bluesky
  • LinkedIn
  • Mail
  • WhatsApp
  • YouTube
  • X

Bedrijfsinformatie

De Jong Pharma Consult
Wipmolen 2
2964 HR Groot-Ammers
Nederland

KvK: 65982568

Contact informatie

phone: +31 412 712 000
cell: +31 6 18 49 39 56

De Jong Pharma Consult 2025 By Themespride